PACIRA BIOSCIENCES, INC. (PCRX) FY2026 Q2 P&L / Income Statement

PACIRA BIOSCIENCES, INC. (PCRX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

192,399,000 US dollars

Cost of goods sold (exclusive of amortization of acquired intangible assets)

44,164,000 US dollars

Gross profit (calculated)

148,235,000 US dollars

Operating expenses (calculated)

143,968,000 US dollars

Income from operations

4,267,000 US dollars

Total other expense, net

negative 1,712,000 US dollars

Income (loss) before income taxes

2,555,000 US dollars

Income tax benefit (expense)

negative 2,098,000 US dollars

Net income (loss)

4,653,000 US dollars

Net product sales

190,493,000 US dollars

Royalty revenue

1,906,000 US dollars

Research and development

30,243,000 US dollars

Selling, general and administrative

91,809,000 US dollars

Amortization of acquired intangible assets

14,322,000 US dollars

Other operating expenses, net

7,594,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.